Shockwave shares are trading higher Tuesday following a report suggesting Johnson & Johnson is in talks to acquire the company. People familiar with the matter say that a deal to acquire the company ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund ...

(Bloomberg) -- Johnson & Johnson agreed to acquire Shockwave Medical Inc. for about $13.1 billion to bolster its expansion into making medical devices to treat heart disease. J&J will pay $335 a share ...

Shares of Shockwave Medical SWAV are up almost 15% so far this week. Majority of this gain is likely due to acquisition rumors. According to a report by the Wall Street Journal, Johnson & Johnson JNJ ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the ...

ShockWave Medical, Inc. SWAV is well-poised for growth, backed by its research and development (R&D) efforts, and its focus on clinical studies. Shares of this presently Zacks Rank #2 (Buy) player ...

As we move towards year-end 2023, I am assembling a list of potential healthcare tickers that are worthy of consideration for a spot in one of my three healthcare portfolios (speculative, growth, ...

SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV) (“Shockwave Medical”) announced today the pricing of its offering of $650.0 million aggregate principal amount of ...

Johnson & Johnson is moving to expand its position in cardiovascular intervention with the acquisition of California-based Shockwave Medical Inc. J&J and the target announced a definitive agreement ...

Johnson & Johnson on Friday announced it would acquire heart device firm Shockwave Medical for $13.1 billion. It’s J&J’s second billion-dollar deal in the cardiovascular space in two years, following ...

Shockwave Medical, Inc. (“Shockwave”) owns U.S. Patent No. 8,956,371 (“the ’371 patent”). This patent is directed to the treatment of atherosclerosis through intravascular lithotripsy (“IVL”). The ...

Shockwave Medical's Q2 results exceeded revenue expectations but fell short on earnings. The bottom-line shortfall came amid acquisition expenses and headcount expansion to support growth. The company ...